Burned-Out Autoimmune Disease: A Multicenter Case Series Revealing a Distinct Clinical Phase and Its Implications for Immunosuppressive Therapy.

Background and objective Distinguishing active inflammation from irreversible organ damage in autoimmune diseases remains a major clinical challenge and may result in the inappropriate continuation of immunosuppressive therapy. The concept of "burned-out" autoimmune disease, in which inflammatory activity subsides following irreversible tissue damage, remains underrecognized. This study aimed to describe the burned-out phase across multiple autoimmune diseases and to propose a cross-disease clinical framework to differentiate active inflammation from irreversible damage. Methods We conducted a multicenter case series involving seven patients who were managed across tertiary care hospitals in Kuwait. The diseases included were lupus nephritis (n = 3), antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (n = 1), polyarteritis nodosa-like vasculitis (n = 1), and axial spondyloarthritis (n = 2). Clinical, laboratory, imaging, and histopathological data were collected and analyzed. Results All patients demonstrated clear evidence of prior active autoimmune disease followed by progression to irreversible organ damage, including end-stage renal disease (ESRD), vascular ischemia, and structural ankylosis. Subsequently, sustained clinical and serological quiescence was observed despite minimal or no immunosuppressive therapy. Continued immunosuppression in one case was associated with a fatal opportunistic infection. Disease activity during follow-up was retrospectively assessed using disease-specific validated measures - including the Birmingham Vasculitis Activity Score (BVAS)-based assessment for vasculitis, the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)-based serological assessment for lupus nephritis, and Axial Spondyloarthritis Disease Activity Score (ASDAS)/Assessment of Spondyloarthritis International Society (ASAS)-based assessment for axial spondyloarthritis - all of which supported inactive disease states in burned-out cases. Conclusions Burned-out autoimmune disease represents a clinically relevant but underrecognized phase across multiple conditions. Failure to distinguish this state from active inflammation may result in unnecessary and potentially harmful immunosuppressive therapy. Our findings support the need for a structured clinical approach to differentiate irreversible damage from ongoing disease activity. Further prospective studies are required to validate this concept and refine its clinical application.